Background: Currently, all patients presenting with asymmetrical sensorineural hearing loss and/or unilateral audiovestibular dysfunction (i.e. tinnitus, dizziness) undergo MRI, leading to a substantial amount of MRIs with negative findings as the incidence of vestibular schwannoma (VS) in this screening population varies between 1% and 4.7% (i.e. more than 95% of MRIs are negative for VS). Objective of review: The aim was to assess the diagnostic accuracy of different non-imaging screening protocols that can be used prior to MRI to select patients at high risk of VS. Type of review: Diagnostic review and meta-analysis. Search strategy: We systematically searched MEDLINE, Embase and The Cochrane Library as from inception up to 28 July 2016. We included studies that compared nonimaging screening protocols to MRI as gold reference standard. Evaluation method: Methodological quality was assessed by two independent reviewers using the Quality Assessment of Diagnostic Accuracy Studies tool. Data necessary to complete 2 9 2 tables were obtained, and patient, study, screening and imaging characteristics were extracted. We
calculated sensitivity and specificity of all tests and obtained pooled estimates using a bivariate random effects model. Results: We analysed 12 studies (4969 patients) of poor to moderate quality according to the quality assessment. Most studies tested diagnostic accuracy of multiple screening protocols. Five pure-tone audiometry (PTA) protocols were studied by multiple authors; pooled estimates for sensitivity ranged from 88% [95% CI: 84-91] to 91% [95% CI: 52-99] and specificity from 31% [95% CI: ] to 58% [95% CI: 49-65]. Due to heterogeneity, we were unable to pool other tests. In five studies testing auditory brainstem response, sensitivity values ranged from 37% [95% CI: ] to 100% [95% CI: 40-100] and specificity from 57% to 96% [95% CI: 87-100]. Two authors studied PTA shape as a screening test. Presenting symptoms, electronystagmography, caloric irrigation and hyperventilation test were assessed by one study each. All reported low diagnostic accuracy. Conclusions: All identified studies had a moderate-to-high risk of bias, and none of the currently available non-imaging screening protocols appear to be accurate in detecting VSs.
The incidence of vestibular schwannoma (VS) is estimated at 0.3-1.9 per 100 000 individuals per year. [1] [2] [3] [4] The majority of patients with a VS present with slowly progressing symptoms, such as asymmetrical hearing loss, vestibular complaints and/or asymmetrical tinnitus. 5, 6 These complaints are common and not specific for VS patients. If pure-tone audiometry (PTA) confirms asymmetrical sensorineural hearing loss, electronystagmography reveals vestibular asymmetry, and/or the patient reports asymmetrical tinnitus, a magnetic resonance imaging (MRI) examination will follow to exclude the presence of VS.
Currently, T1-weighted MRI using gadolinium-based contrast (GdT1-MRI) is the gold standard in the diagnostic work up of these patients. However, some hospitals also perform T2-weighted MRI (T2-MRI), either as additional examination next to GdT1-MRI or more frequently replacing GdT1-MRI. Whenever sufficient visibility of the cochlea, labyrinth and the VIIth and VIIIth cranial nerve in the cerebellopontine angle and internal auditory canal is achieved by high-resolution T2-MRI, it probably has comparable diagnostic accuracy to GdT1-MRI in detecting VS. 5 Currently, all patients presenting with asymmetrical sensorineural hearing loss and/or unilateral audiovestibular dysfunction (i.e. tinnitus, dizziness) undergo MRI, leading to a substantial amount of MRIs with negative findings as the incidence of VS in this screening population varies between 1% and 4.7% (i.e. more than 95% of MRIs are negative for VS). [7] [8] [9] [10] Based on Dutch cost data, a screening MRI costs €206 (approximately US$231) per patient at risk of VS. 4, 11 If we could reduce the amount of patients needing MRI by improving selection criteria (i.e. reduce the amount of MRIs with negative findings), this would lead to a reduction in unnecessary examinations and costs. Using a potential new diagnostic strategy, high-risk patients would still undergo MRI to confirm the diagnosis. Based on MRI findings, tumour location and size can be evaluated to determine further action.
The aim of this diagnostic review and meta-analysis was to assess the diagnostic accuracy of different non-imaging screening protocols that can be used to identify patients with VS.
Methods

Searches
We systematically searched MEDLINE (OvidSP), Embase (OvidSP) and the Cochrane Library from inception up to 28 July 2016 for studies testing non-imaging screening protocols to identify patients with VS. The search query combined synonyms for MRI, asymmetrical sensorineural hearing loss, unilateral audiovestibular dysfunction and VS (see Appendix S1 for the complete search strategy). We also performed a reference and related article search. Duplicate articles were manually filtered using the bibliographic EndNote database, version X5 (Thomas Reuters, New York City, NY, USA). There was no limitation in publication year or status nor in language.
Study selection
We included studies with a diagnostic study design, presenting original study data, both prospective and retrospective. They had to compare at least one non-imaging screening protocol to MRI findings, inpatients with asymmetrical sensorineural hearing loss and/or unilateral audiovestibular dysfunction, considered at risk of VS. We included all types of screening protocols (e.g. using symptoms, PTA, or other diagnostic tests). Both GdT1-MRI and T2-MRI were used for this review. Furthermore, they had to provide sufficient data to construct a 2x2 contingency table. We excluded opinion articles, animal studies, (systematic) reviews, case reports and studies using other imaging techniques than MRI as reference test. Two reviewers (MH and MS) independently assessed the eligibility of the identified articles. Any disagreements were resolved by discussion with a third reviewer (MR).
Data extraction and quality assessment
Two authors (MH and MS) extracted data independently using a pre-defined form, including data on patient, study, screening and imaging characteristics. Patient characteristics comprised age, gender and presenting symptoms. Study characteristics included sample size and study type. Screening characteristics comprised incidence of VS, index tests and target disease. Imaging characteristics included MRI field strength, sequence and assessment. We contacted authors of different articles to obtain absolute data not displayed in their publications, or for clarification (see Appendix S2 for an overview of missing data, assumptions and translations).
Next, we assessed the risk of bias and applicability of the studies using the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) scoring system. 12 This is a validated tool for assessment of the methodological quality and applicability of diagnostic accuracy studies. Four domains are distinguished: (i) patient selection, which describes the process of patient selection and included patients; (ii) index test, describing the test under study and how it was conducted and interpreted; (iii) reference standard, describing the used reference standard and how it was conducted and interpreted; and (iv) flow and timing, describing the flow of patient in-and exclusion and the time interval between index test and reference standard. Two independent reviewers (MH and MS) performed the quality assessment. Any disagreements were resolved by discussion with a third reviewer (MR).
Analysis
We summarised data from each study in 2 9 2 tables of true-positive, false-positive, true-negative and false-negative values and calculated sensitivity and specificity values. Authors of studies that did not report all sufficient data were asked to provide additional information. To calculate sensitivity and specificity measurements at study level, we used Review Manager (RevMan) software, version 5.3 (The Nordic Cochrane Centre, The Cochrane Collaboration, 2014). To show variation and explore heterogeneity for sensitivity and specificity, we drew forest plots. Where possible, we provided pooled estimates of sensitivity and specificity with 95% confidence intervals (95% CIs). We used R version 3.2.3 (The R Foundation for Statistical Computing, Vienna, Austria, 2015) using the mada package to carry out the meta-analyses. We wanted to study heterogeneity in more detail, by performing sensitivity analyses of clinically relevant covariates (age, VS size and location, and MRI field strength and sequence).
Results
Literature search
Our search yielded 1788 unique records, of which 60 remained after screening titles and abstracts (see also Fig. 1 ). We reviewed full texts of these studies for eligibility and excluded 48. Studies were excluded because of their study design (case reports, editorials/comments, reviews, guidelines), the same data were used in another study, there was lack of a control group or reference test, or because they had a different domain, determinant or outcome. Finally, 12 studies were included, covering a total of 4969 patients. We did not retrieve additional items after screening references and related articles. Table 1 provides an overview of the patients included in the different studies. Studies providing information on sex included 806 (50.7%) men and 784 (49.3%) women. [13] [14] [15] [16] [17] The mean age reported varied from 45 to 57 years. [13] [14] [15] [16] [17] The incidence of VS ranged from 1.4% to 39.6% in the included cohort studies. 13, [16] [17] [18] [19] [20] Most other studies were case-control studies. Several authors studied multiple screening protocols in their study population. 14, 15, 17, 18, 21, 22 Six studies used PTA as index test, comprising 3116 patients. 14, [17] [18] [19] 21, 22 Five of these 14, 17, 18, 21, 22 tested specific PTA protocols (hearing thresholds at different frequencies) that had been published before in 2616 patients, and two 14, 19 tested different PTA shapes (description of the PTA shape without providing specific thresholds, e.g. flat and mountain) using 925 patients. ABR was tested in five studies in a total of 652 patients. 13, 15, 16, 22, 23 Hyperventilation test, electronystagmography, caloric irrigation, presenting symptoms and a prediction model were tested in one study each, comprising 102, 100, 102, 881 and 420 patients, respectively. 15, 20, 22, 24 Quality assessment
Study characteristics
Overall, the quality of included studies was low to moderate (Fig. 2) . Nine studies found a high risk of bias in ≥1 domain. For the domains patient selection, index test, reference standard, and flow and timing, a high or unclear risk of bias was scored for 9, 11, 12 and 5 studies, respectively. The risk of bias in index and reference test categories was generally scored unclear, because there was uncertainty about blinding, and MRI sequence and/or field strength were not provided. For the domains patient selection, index test and AND AND Fig. 1 . Flow chart of search and selection of studies.
Non-imaging screening protocols for VS 817 ? Radiologist reference standard, respectively, only 1, 1 and 2 studies scored high on concerns regarding applicability. Thus, for the majority of the articles, there was low concern that applicability of the articles did not fit the review question. No studies were excluded from the analysis based on the quality assessment.
Diagnostic accuracy of PTA, ABR and other tests Table 2 provides an overview of asymmetrical sensorineural hearing loss definitions of the different PTA protocols. Forest plots representing the diagnostic accuracy of each protocol as tested in the individual studies can be found in Figure S1 . Sensitivities were high for all PTA protocols. Specificities, however, did not exceed 70%. Five PTA protocols were studied by multiple authors in studies with similar incidences of VS; pooled estimates for sensitivity and specificity are displayed in Table 3 24 
Sensitivity analysis
We were unable to explore heterogeneity in more detail, because of the limited amount and quality of data. ?, unclear/unknown; +/À, either with or without.
ABR, auditory brainstem response audiometry; (A)(S)HL, (asymmetric) (sensorineural) hearing loss; ENG, electronystagmography; C, cohort; CC, case-control; CPA, cerebellopontine angle; GdT1, T1 with administration of gadolinium; HVT, hyperventilation test; NRT, non-randomised trial; PTA, pure-tone audiometry; SDS, speech discrimination score; (U)AD, (unilateral) audiovestibular dysfunction; VS, vestibular schwannoma.
Non-imaging screening protocols for VS 819 Fig. 2 . Overview QUADAS-2 results: risk of bias and concerns regarding applicability. 
Strengths and limitations
This is the first systematic review and meta-analysis studying different screening protocols for patients at risk of VS. As others have previously studied one screening method, we gathered evidence of multiple screening methods in this review. 5 The major strength of this diagnostic review is that we made no restrictions to the search in terms of publication year, status or in language. Furthermore, we were able to provide some pooled estimates of relatively large study populations that tested the same PTA protocols.
Some potential limitations should also be discussed. First, we were not able to obtain pooled estimates of all tests, because incidence rates among studies differed or protocols and/or thresholds of the described tests were too heterogeneous. Pooling of these studies would result in unreliable estimates. 25 Second, the included studies often had a lack of important details. For example, for most studies, it was unclear whether results of the index test were interpreted without knowledge of the reference standard; therefore, the risk of biased results was unclear. Furthermore, details about MRI (field strength, sequence and assessment) were lacking in most studies; therefore, it was not always possible to assess its ability to correctly detect lesions. Third, we performed one overall search for all tests instead of separate searches for each index test. We do, however, believe we have identified all available evidence, as we did not encounter additional items during screening of references and related articles. Fourth, we intended to study heterogeneity in more detail by performing sensitivity analyses of the clinically relevant covariates (age, VS size, location of VS and MRI field strength and sequence). Unfortunately, this was not possible due to the limited amount and quality of data. Finally, only one study looked at tinnitus as an isolated symptom. It did not provide enough data to draw final conclusions regarding the question whether asymmetrical tinnitus without asymmetry on PTA might also be an ?, Unclear/unknown; CI, confidence interval; ABR, auditory brainstem response, ms: millisecond.
Non-imaging screening protocols for VS 821 indication for MRI. 20 It therefore remains a challenge to select high-risk patients from this particular group.
Implications for clinical practice
It would be ideal to use a relatively simple, low-cost test as a first screening tool for VS, such as PTA. Most screening protocols published in this review make use of PTA as a screening tool. 14, [17] [18] [19] 21, 22 Based on the pooled results from this meta-analysis, AAO-HNS, Obholzer 1 and Sunderland protocols appeared to have highest sensitivities in detecting VS, but all three have poor specificities. 14, 17, 21 With a lack of better alternatives, these tests could potentially lead to a reduction in the number of patients needing MRI. Patients with a positive non-imaging screening test should still undergo MRI to confirm the diagnosis and to get information on tumour size and location, that is to make well-informed decisions regarding treatment. However, when using these protocols up to 9% of VSs would be missed (false-negative rate). At this moment, we cannot assess what consequences false-negative results have on clinical outcome and costs; therefore, it is difficult to assess the impact of a false-negative rate of 9%. Moreover, one needs to consider the large confidence intervals around the point estimates of sensitivity and specificity rates, and the low-to-moderate quality of the included studies. This uncertainty could also explain why none of the PTA protocols are currently being used in an international guideline for VS screening, despite their fairly high sensitivity values. Before MRI became the standard, ABR was frequently used to detect VS. The ability of ABR to detect small intracanalicular lesions is limited, and ABR cannot be performed in patients with severe hearing loss of more than about 70 dB, while these patients are part of the screening population. 5, 13, 15 This results in a relatively small population in which ABR could be considered a reliable method for VS screening. Moreover, ABR is a relatively costly and time-consuming investigation and its reported diagnostic accuracy varies among included studies; therefore, we find it an unsuitable screening tool for VS. 5, 13, 15, 16, 22, 23 Implications for research This review shows that reliable screening protocols are currently not available. If one aims to detect every single case of VS, every patient with the slightest asymmetrical sensorineural hearing loss and/or unilateral audiovestibular dysfunction should undergo MRI. However, when we look at the amount of negative MRIs in the population screened for VS (more than 95% negative for VS), we consider this a great waste of resources. Based on Dutch cost prices, an average of €177 (approximately US$198) could be saved per patient at risk of VS, when we would be able to avoid all MRIs negative for pathology. 11 With the current discussions about the use of resources and overdiagnosis in mind, we believe there is a need for more reliable screening protocols to identify VS in patients with asymmetrical sensorineural hearing loss and/or unilateral audiovestibular dysfunction. 26 It would also be worthwhile to investigate which VSs will require future treatment and focus on diagnosing these VSs in particular, because it is known that two-thirds of VSs in a wait and scan policy remain stable for years without a need for treatment. 27, 28 Our results confirm that none of the currently available non-imaging screening protocols appear to be accurate in detecting VS.
Keypoints
• We have assessed the diagnostic accuracy of different non-imaging screening protocols that can be used prior to MRI to select patients at high risk of VS.
• In our meta-analysis, three PTA protocols (AAO-HNS, Obholzer 1 and Sunderland) reached highest sensitivities of 91% in detecting VS, but all three have poor specificities.
• All identified studies had a moderate-to-high risk of bias, and none of the currently available non-imaging screening protocols appear to be accurate in detecting VSs.
